Viatris Inc.: Glaucoma, Open-Angle trials

The registry lists 16 Glaucoma, Open-Angle studies with Viatris Inc. as lead sponsor. 0 are open to participants now and 2 have results posted.

Phase 2 2Phase 3 9Phase 4 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Non Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated With XALATAN®CompletedNCT00486252Results posted
• A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).CompletedNCT00383019Phase 3Results posted
• A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular HypertensionCompletedNCT01379144Phase 2
• A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In PatientsCompletedNCT00856622Phase 3
• Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.CompletedNCT00801437
• A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within ScandinaviaCompletedNCT00751062Phase 3
• A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United KingdomCompletedNCT00751049Phase 3
• A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle GlaucomaCompletedNCT00647101Phase 4
• Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in CanadaCompletedNCT00334750
• Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery DeviceWithdrawnNCT00283764Phase 3
• A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With GlaucomaCompletedNCT00277498Phase 3
• Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular PressureCompletedNCT00230763Phase 3
• Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular HypertensionCompletedNCT00219596Phase 3
• A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With GlaucomaCompletedNCT00159653Phase 3
• Corneal Versus Conjunctival Delivery Using a Delivery DeviceWithdrawnNCT00143429Phase 2
• A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ GlaucomaCompletedNCT00140049Phase 4